Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.

[1]  S. Choi,et al.  Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation , 2017, Gastric Cancer.

[2]  J. Han,et al.  Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma , 2016, Journal of pathology and translational medicine.

[3]  W. Yang,et al.  Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients , 2016, Leukemia & lymphoma.

[4]  G. Avvisati,et al.  High density of CD68+/CD163+ tumour‐associated macrophages (M2‐TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B‐cell lymphoma , 2015, Hematological oncology.

[5]  R. Gascoyne,et al.  Tumor-associated macrophages in diffuse large B-cell lymphoma , 2015, Haematologica.

[6]  J. Delabie,et al.  Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial , 2015, Haematologica.

[7]  L. Nguyen,et al.  Clinical blockade of PD1 and LAG3 — potential mechanisms of action , 2014, Nature Reviews Immunology.

[8]  E. Giné,et al.  Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy , 2014, Annals of Hematology.

[9]  R. Gascoyne,et al.  The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.

[10]  D. Heo,et al.  An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone , 2014, Leukemia & lymphoma.

[11]  D. Cheresh,et al.  A wake-up call for hibernating tumour cells , 2013, Nature Cell Biology.

[12]  F. Schuetz,et al.  Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications , 2013, Cancer and Metastasis Reviews.

[13]  Yi Xia,et al.  High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma , 2012, Medical Oncology.

[14]  B. Silva-Santos,et al.  The split nature of tumor-infiltrating leukocytes , 2012, Oncoimmunology.

[15]  George Coukos,et al.  T-regulatory cells: key players in tumor immune escape and angiogenesis. , 2012, Cancer research.

[16]  A. Loskog,et al.  T regulatory cells in B‐cell malignancy – tumour support or kiss of death? , 2012, Immunology.

[17]  J. Friedberg.  Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.

[18]  P. Hogendoorn,et al.  The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone , 2011, Virchows Archiv.

[19]  K. Pienta,et al.  Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for Bone Metastatic Tumors , 2011, Clinical Cancer Research.

[20]  R. Gascoyne,et al.  Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Cardoso,et al.  Stem cell regulatory niches and their role in normal and malignant hematopoiesis , 2010, Current opinion in hematology.

[22]  A. Trumpp,et al.  Awakening dormant haematopoietic stem cells , 2010, Nature Reviews Immunology.

[23]  A. Marini,et al.  Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. , 2009, American journal of clinical pathology.

[24]  H. Nilsson‐Ehle,et al.  Expression of CD68+ tumor‐associated macrophages in patients with diffuse large B‐cell lymphoma and its relation to prognosis , 2008, Pathology international.

[25]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[26]  Guan-Cheng Huang,et al.  Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell Lymphomas Correlate with Prognoses , 2007, Clinical Cancer Research.

[27]  T. Reiman,et al.  Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. , 2007, Blood.

[28]  H. Nilsson‐Ehle,et al.  The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma , 2007, British journal of haematology.

[29]  J. Matthews,et al.  The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement , 2006, European journal of haematology.

[30]  C. Meijer,et al.  Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas , 2004, Leukemia.

[31]  D. Weisenburger,et al.  Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.